Matinas BioPharma Holdings, Inc.
$0.33 +$0.09 (+37.53%) 1D After hoursKey Metrics
The Story So Far
LAST 6 MONTHS PRIMARY SOURCES ONLY-
Jul 27
The stock moved +37.5% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Jul 27 -
Jul 24
A material event was filed (Form 8-K).
8-K - Matinas BioPharma Holdings, Inc. (0001582554) (Filer)
RECEIPT: SEC FORM 8-K, TIMESTAMPED -
Jul 24
From its Jun 1 high, the share price fell 72%.
Peak close $0.87 on Jun 1; trough close $0.24 on Jul 24. The drawdown is the fact — the chapters around it are the context.
RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -72% -
Jul 16
Money rotated out of high-beta cohorts market-wide.
High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.
RECEIPT: ROTATION GAUGE, LIVE -
Jul 13
The stock moved -36.4% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Jul 13
The story updates itself as events post · The wolf reports; you decide
Snapshot
About Matinas BioPharma Holdings, Inc.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.
Wolf Grade COMING SOON
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.